Key Takeaway: An exploratory omics study presented at the Society for Neuroscience annual meeting highlights the potential roles of sigma-2 receptor modulators in a rat model of Parkinson's disease. The findings suggest these modulators could have therapeutic implications. This research adds to the growing body of knowledge regarding treatment options for Parkinson's.
Price reaction · baseline $1 (2023-11-09 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+6.5%
day 1
+3%
day 3
+5%
Market Sentiment Analysis
POSITIVE FACTORS
Exploratory study shows promising results for sigma-2 receptor modulators.
Research presented at a prestigious conference enhances visibility.
Potential therapeutic implications for Parkinson's disease.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Reaver AJ, Lizama BN, Pandey K, et al. Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease . Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting ; Washington DC.
Frequently Asked Questions
What was the focus of the exploratory omics study?
The study focused on the potential roles of sigma-2 receptor modulators in Parkinson's disease.
Where was the research presented?
The research was presented at the Society for Neuroscience annual meeting in Washington DC.
What model was used in the study?
The study utilized an AAV1/2A53T-aSyn rat model of Parkinson's disease.
What are sigma-2 receptor modulators?
Sigma-2 receptor modulators are compounds that may influence neurological conditions.